Clofibrate


Concise Prescribing Info
Indications/Uses
Hyperlipidaemias.
Dosage/Direction for Use
Adult: PO 2 g/day in divided doses.
Administration
May be taken with or without food. May be taken w/ meals to reduce GI discomfort.
Contraindications
Severe renal or hepatic impairment; hypoalbuminaemia; primary biliary cirrhosis; gallbladder disease; nephrotic syndrome; pregnancy; lactation.
Special Precautions
Renal impairment; discontinue if myotoxicity is suspected or creatine kinase conc increases significantly. Caution in patients with peptic ulcer.
Adverse Reactions
Anorexia; nausea; gastric discomfort; stomatitis; headache; dizziness; vertigo; fatigue; skin reactions; alopoecia; impotence; anaemia; leucopenia; myotoxicity; thrombocytopenia; vomiting; diarrhoea; dyspepsia; flatulence; wt gain; drowsiness; hepatomegaly. Increased incidence of cholecystitis, gallstones and pancreatitis.
Drug Interactions
May increase anticoagulant effects of acenocoumarol, warfarin and phenindione. Increased risk of muscle toxicity with HMG-CoA reductase inhibitors. May enhance hypoglycaemic effect of antidiabetic drugs. May cause rhabdomyolysis or neuromyopathy when used with colchicine. Risk of rhabdomyolysis with sirolimus. May increase risk of gallstone formation when used with ezetimibe. Clearance may be increased by oral contraceptives. Efficacy may be reduced with rifampicin. Serum levels may be doubled by probenecid.
ATC Classification
C10AB01 - clofibrate ; Belongs to the class of fibrates. Used in the treatment of hyperlipidemia.
Disclaimer: This information is independently developed by CIMS based on clofibrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in